X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The financing will be used to advance generative AI-powered drug discovery platform and product development for novel treatments and therapeutic approaches.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Fidelity Management & Research Company
Deal Size: $81.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing September 27, 2023
Details:
In partnership with Takeda, Evozyne will create novel protein sequences for advancement as gene therapies for up to four rare disease targets using Evozyne’s protein engineering platform.
Lead Product(s): Undisclosed
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: $400.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration April 05, 2022
Details:
In partnership with Takeda, Evozyne will create novel protein sequences for advancement as gene therapies. At completion Takeda has the option to obtain an exclusive license to develop and commercialize the novel protein sequences as part of its gene therapy program.
Lead Product(s): Synthetic proteins
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 25, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
